An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis
Open Access
- 24 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 146 (4), 945-951
- https://doi.org/10.1007/s00432-019-03119-3
Abstract
Purpose Systemic mastocytosis (SM) is characterized by the expansion of clonal mast cells that infiltrate various organ systems. The extent of organ infiltration and subsequent organ damage distinguishes between indolent SM (ISM) defined by a nearly normal life expectancy and advanced SM (AdvSM) defined by poor prognosis. In ISM, measurement of the bone mineral density (BMD) frequently reveals osteoporosis. In contrast, the clinical implication of an increased BMD and osteosclerosis remains unclear. Methods BMD was evaluated in 61 patients with mastocytosis (ISM, n = 29, 48%; AdvSM, n = 32, 52%). We correlated the prevalence of osteoporosis, increased BMD and osteosclerosis with clinical parameters, disease variant and prognosis. Results Osteoporosis was detected in 11/29 (38%) patients with ISM but only in 2/32 (6%) patients with AdvSM (p = 0.004). An increased BMD was detected in 1/29 (3%) patients with ISM and 24/32 (75%) patients with AdvSM (p < 0.001) while osteosclerosis was only detected in AdvSM patients (16/32, 50%). AdvSM patients with increased BMD had higher levels of bone marrow mast cell infiltration, higher serum tryptase and alkaline phosphatase levels compared to ISM as well as higher number of high-molecular risk mutations (p < 0.05). In addition, we found that the prognosis of AdvSM patients with increased BMD is inferior compared to those without increased BMD (median overall survival 3.6 years versus not reached, p = 0.031). Conclusions Osteoporosis is a common feature in ISM but not in AdvSM. An increased BMD is frequently present in AdvSM but not in ISM and is associated with more advanced disease and inferior outcome.This publication has 31 references indexed in Scilit:
- MARS: Mutation-Adjusted Risk Score for Advanced Systemic MastocytosisJournal of Clinical Oncology, 2019
- International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort studyThe Lancet Haematology, 2019
- Bone Involvement and Osteoporosis in MastocytosisImmunology and Allergy Clinics of North America, 2014
- Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosisBone, 2011
- Systemic mastocytosis and bone involvement in a cohort of 75 patientsAnnals Of The Rheumatic Diseases, 2010
- Osteoporosis with vertebral fractures in young males, due to bone marrow mastocytosis: a report of two cases.2010
- Two patients with osteoporosis: initial presentation of systemic mastocytosisJournal of Bone and Mineral Metabolism, 2008
- Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response CriteriaEuropean Journal of Clinical Investigation, 2007
- Elevated Tryptase Levels Are Associated with Greater Bone Density in a Cohort of Patients with MastocytosisInternational Archives of Allergy and Immunology, 2006
- Diagnostic criteria and classification of mastocytosis: a consensus proposalLeukemia Research, 2001